Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

13 févr. 2026 14h56 HE | Source: Robbins LLP

INO Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Inovio Pharmaceuticals, Inc. Class Action

Robbins LLP is Investigating Allegations that Inovio Pharmaceuticals, Inc. (INO) Misled Investors Regarding Approval for its CELLECTRA Device
13 févr. 2026 13h04 HE | Source: Robbins LLP

FRMI Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Fermi Inc. Class Action

Robbins LLP is Investigating Allegations that Fermi Inc. (FRMI) Misled Investors Regarding its Business Prospects
12 févr. 2026 12h14 HE | Source: Robbins LLP

PLUG Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Plug Power Inc. Class Action

Robbins LLP is Investigating Allegations that Plug Power Inc. (PLUG) Misled Investors Regarding its Ability to Receive and Utilize the DOE Loan
09 févr. 2026 16h33 HE | Source: Robbins LLP

TCPC Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the BlackRock TCP Capital Corp. Class Action

Robbins LLP is Investigating Allegations that BlackRock TCP Capital Corp. (TCPC) Misled Investors Regarding its Business Prospects
09 févr. 2026 16h16 HE | Source: Robbins LLP

MREO Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Mereo BioPharma Group plc Class Action

Robbins LLP is Investigating Allegations that Mereo BioPharma Group plc (MREO) Misled Investors Regarding Phase 3 Orbit and Cosmic Studies for Setrusumab
09 févr. 2026 16h06 HE | Source: Robbins LLP

RARE Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Ultragenyx Pharmaceutical Inc. Class Action

Robbins LLP is investigating claims that Ultragenyx (RARE) misled investors about Phase III Orbit and Cosmic trials for setrusumab.
09 févr. 2026 16h00 HE | Source: Robbins LLP

ORCL Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Oracle Corporation Class Action

Robbins LLP is Investigating Allegations that Oracle Corporation (ORCL) Misled Investors Regarding its Data Center Capabilities for AI Infrastructure
09 févr. 2026 15h22 HE | Source: Robbins LLP

CLEUF Class Action Notice: Robbins LLP Reminds Investors of the Lead Deadline in the China Liberal Education Holdings Ltd. Class Action

Robbins LLP is Investigating Allegations that China Liberal Education Holdings Ltd. (CLEUF) Participated in a Fraudulent Pump-and-Dump Scheme
06 févr. 2026 16h10 HE | Source: Robbins LLP

PMI Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Picard Medical, Inc. Class Action

Robbins LLP is Investigating Allegations that Picard Medical, Inc. (PMI) was the Subject of a Fraudulent Stock Promotion Scheme
06 févr. 2026 15h59 HE | Source: Robbins LLP

METC Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Ramaco Resources, Inc. Class Action

Robbins LLP is Investigating Allegations that Ramaco Resources, Inc. (METC) Overstated Development Progress at the Company's Brook Mine

Page suivante